About this trial

This study aims to evaluate the efficacy and safety of Remimazolam, either used alone or in combination with Propofol, for moderate sedation anesthesia during endoscopic therapies or examinations. Additionally, it seeks to explore whether their combination can further enhance the quality of patient anesthesia and recovery outcomes.

Eligibility criteria

Qualifiers

Subjects are between 20-80 years old.

Anesthesiologists rated ASA as between I and III.

Patients undergoing upper gastrointestinal endoscopic examination or therapy.

Disqualifiers

Allergy to Propofol, Remimazolam, or opioid medications.

Emergency surgery.

Pregnancy.

History of malignant hyperthermia.

Trial design

Treatments tested in this trial

  • Remimazolam
  • Propofol

Treatment groups

90 Participants
are divided into 3 treatment groups

Locations

1
Kaohsiung Veterans General Hospital81362, Kaohsiung City Taiwan

Sponsors and collaborators

Kaohsiung Veterans General Hospital.

Lead sponsor